Published in J Immunol on January 15, 1987
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest (1988) 2.15
Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med (1989) 1.97
Human monocyte-derived macrophage phagocytosis of senescent eosinophils undergoing apoptosis. Mediation by alpha v beta 3/CD36/thrombospondin recognition mechanism and lack of phlogistic response. Am J Pathol (1996) 1.64
The organization and consequences of eicosanoid signaling. J Clin Invest (2003) 1.36
Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci U S A (2003) 1.30
Mast cell activation enhances airway responsiveness to methacholine in the mouse. J Clin Invest (1993) 1.26
Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med (1994) 1.19
Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. J Exp Med (1995) 1.14
Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy (2006) 1.09
Mediator and cytokine mechanisms in asthma. Thorax (1993) 0.97
Haematological effects of inhalation of N-formyl-methionyl-leucyl-phenylalanine in man. Thorax (1992) 0.93
Regulation of human eosinophil degranulation and activation by endogenous phospholipase A2. J Clin Invest (1993) 0.89
Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol (1992) 0.87
Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP. J Clin Invest (1991) 0.82
Release of O2- and LTC4 by murine eosinophils: role of intra- and extracellular calcium. Immunology (1990) 0.81
The role of eosinophils in asthma. Lung (1990) 0.79
Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics. Immunology (1993) 0.79
The role of arachidonic acid metabolites in local and systemic inflammatory processes. Drugs (1987) 0.79
Enhancement of leukotriene C4 release from primate airway macrophages by cellular interactions. Br J Pharmacol (1989) 0.77
Leukotriene receptor antagonists: clinical effects. J R Soc Med (1997) 0.76
Pulmonary epithelial cancer cells and their exosomes metabolize myeloid cell-derived leukotriene C4 to leukotriene D4. J Lipid Res (2016) 0.76
Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med (1976) 17.77
A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet (1997) 10.93
Standardization of bronchial inhalation challenge procedures. J Allergy Clin Immunol (1975) 10.52
CARBOHYDRATE METABOLISM IN ADDISON'S DISEASE. J Clin Invest (1940) 9.89
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science (1997) 6.00
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. J Immunol (1971) 5.41
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science (2001) 5.22
Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol (2001) 5.02
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3. J Immunol (1969) 4.38
A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med (1971) 4.07
Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med (1990) 4.06
Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med (1985) 4.00
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
A neutrophil-immobilizing factor derived from human leukocytes. I. Generation and partial characterization. J Exp Med (1972) 3.75
Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature (2000) 3.61
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
THE EFFECT OF 17-HYDROXYCORTICOSTERONE AND RELATED ADRENAL CORTICAL STEROIDS ON SODIUM AND CHLORIDE EXCRETION. Science (1941) 3.45
Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology (2005) 3.44
Triggering myocardial infarction by marijuana. Circulation (2001) 3.36
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med (1972) 3.31
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A (1983) 3.30
The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest (1984) 3.26
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol (1983) 3.18
Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A (1980) 3.18
Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet (1996) 3.17
The complement system of man. I. N Engl J Med (1972) 3.09
Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J Exp Med (1967) 3.08
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat (2001) 3.07
A pre-albumin activator of prekallikrein. J Immunol (1970) 2.95
Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A (1980) 2.94
Molecular genetics of human blue cone monochromacy. Science (1989) 2.92
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Native heparin from rat peritoneal mast cells. J Biol Chem (1977) 2.79
Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat (2003) 2.75
Inactivation of slow reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol (1975) 2.73
Clinical diagnosis of the Usher syndromes. Usher Syndrome Consortium. Am J Med Genet (1994) 2.72
Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med (1987) 2.69
Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol (1982) 2.69
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci U S A (1975) 2.56
Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed Proc (1972) 2.55
Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. Nat Genet (2000) 2.53
The complement system in rheumatoid synovitis. I. An analysis of complement component activities in rheumatoid synovial fluids. Arthritis Rheum (1971) 2.53
Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev (2001) 2.52
Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun (1980) 2.49
Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis (1991) 2.43
Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol (1998) 2.42
Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. Nature (1981) 2.41
A pitfall in the surgery of a recurrent aneurysm after coil embolization and its histological observation: technical case report. Neurosurgery (1996) 2.40
Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate. J Exp Med (1971) 2.39
Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem (1981) 2.37
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol (2008) 2.37
The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis. J Immunol (1973) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Hereditary deficiency of the second component of complement (C'2) in man. J Clin Invest (1966) 2.32
The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med (1972) 2.31
Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet (1998) 2.31
Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol (1986) 2.31
Tumor-associated eosinophilotactic factor. N Engl J Med (1974) 2.27
Bardet-Biedl syndrome is linked to DNA markers on chromosome 11q and is genetically heterogeneous. Nat Genet (1994) 2.26
Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol (1998) 2.23
Slow reacting substance of anaphylaxis. Adv Immunol (1969) 2.23
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet (2001) 2.19
Inactivation of slow reacting substance of anaphylaxins (SRS-A) by arylsulfatases. J Immunol (1974) 2.19
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet (1996) 2.18
Docking and scoring--theoretically easy, practically impossible? Curr Med Chem (2006) 2.18